Affiliation:
1. Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji Uni
Abstract
AbstractBackground:The anti-PP1Pk antibody is a rare antibody associated with recurrent spontaneous abortion (RSA) in the first trimester. As it is a rare entity, few reports have been published, especially in China. Currently, there is no specific treatment for RSA associated with anti-PP1Pk antibody because it is a naturally occurring antibody. This study aims to report three cases of RSA associated with the anti-PP1Pk antibody to share our experiences with its management.Methods:The three patients' medical information was obtained from the medical records. Intravenous immunoglobulin and/or plasmapheresis was offered to the patients. We also made an extension research of the related literature about RSA associated with anti-PP1Pk antibody.Results:Although patients received intervention, the maternal anti-PP1Pk antibody titer remained stable and did not decrease. There were no live births. We summarized publications about pregnancy in women with anti-PP1Pk antibodies.Conclusions:Early initiation of plasmapheresis in high-risk patients with anti-PP1Pk antibodies should be strongly considered.
Publisher
Research Square Platform LLC
Reference33 articles.
1. ESHRE guideline: recurrent pregnancy loss;Bender Atik R;Hum Reprod Open,2018
2. treatment of recurrent pregnancy loss: a committee opinion;Evaluation;Fertil Steril,2012
3. Expert Consensus on the diagnosis and treatment of recurrent abortion;Obstetric Group of Obstetrics and Gynecology Branch of Chinese Medical Association;Chin J Obstet Gynecol,2016
4. Recent Advances in Treatment of Recurrent Spontaneous Abortion;Deng T;Obstet Gynecol Surv,2022
5. Efficacy of intravenous immunoglobulin in the treatment of recurrent spontaneous abortion: A systematic review and meta-analysis;Shi Y;Am J Reprod Immunol,2022